From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
BLT-1, a thiosemicarbazone copper chelator, is a selective scavenger receptor B, type 1 (SR-BI) inhibitor. BLT-1 inhibits the transfer of lipids between high-densitylipoproteins (HDL) and cells mediated by SR-BI. BLT-1 is a potent HCV entry inhibitor .
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-densitylipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-densitylipoprotein levels and improve high-densitylipoprotein levels. .
BLT-4 is a specific, reversible inhibitor of scavenger receptor, class B, type I (SR-BI). BLT-4 inhibits the transfer of lipids between high-densitylipoproteins (HDL) and cells mediated by SR-BI. .
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-densitylipoprotein cholesterol (LDLC) and promotion of high-densitylipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
CP-532623 is a CETP inhibitor and elevates high-densitylipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .
16:0 PDP PE belongs to a class of head group modified functionalized lipids. 16:0 PDP PE has been used in preparation of rhodamine high-densitylipoprotein nanoparticle (Rh-HDL NP) synthesis.
APL180 (L-4F) is an apolipoprotein A-I mimic peptide, that improves the anti-inflammatory activity of high-densitylipoprotein (HDL). APL180 can be used in researches of cardiovascular diseases .
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-densitylipoprotein (HDL) and low-densitylipoprotein (LDL) research .
CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-densitylipoprotein (HDL) particles, and induces the release of microparticles .
GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-densitylipoprotein (HDL) cholesterol, decreased low-densitylipoprotein (LDL) and very low-densitylipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-densitylipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases .
CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-densitylipoprotein (HDL) particles, and induces the release of microparticles .
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-densitylipoprotein (HDL) to very-low-densitylipoprotein (VLDL) and low-densitylipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .
Nicomol is an orally active hypolipidemic agent that can increase the high densitylipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-densitylipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC50 of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low densitylipoproteins and elevated high densitylipoprotein levels when administered at 0.05%.
Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-densitylipoprotein cholesterol (non-HDL-C) levels in persistent?hypertriglyceridemia? .
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high densitylipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high densitylipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-densitylipoprotein (HDL) particles, and induces the release of microparticles .
KRES peptide is an apolipoprotein with 4 amino acid residues. KRES peptide interacts with lipids, reduces lipoprotein lipid hydroperoxides (LOOH), activates antioxidant enzymes associated with high-densitylipoprotein. KRES peptide exhibits anti-inflammatory and anti-atherogenic properties. KRES peptide is orally active .
APL180 (L-4F) is an apolipoprotein A-I mimic peptide, that improves the anti-inflammatory activity of high-densitylipoprotein (HDL). APL180 can be used in researches of cardiovascular diseases .
APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-densitylipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases .
CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-densitylipoprotein (HDL) particles, and induces the release of microparticles .
LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high densitylipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
LVGRQLEEFL (mouse) TFA can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) TFA exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) TFA can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high densitylipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death .
Stachybotramide is a natural fungal metabolite with the property of modulating the activity of cholesteryl ester transfer protein (CETP). Stachybotramide stimulates the transfer of cholesteryl esters (CE) from high-densitylipoprotein (HDL) to very-low-densitylipoprotein (VLDL) and low-densitylipoprotein (LDL), increasing the transfer efficiency by 1.3- to 1.5-fold. Stachybotramide slightly reduced the transfer of cholesteryl esters from LDL and VLDL to HDL at 0.5 mM. The effect of Stachybotramide on the transfer of triglycerides (TG) from HDL was not significant. By these results, Stachybotramide was shown to preferentially stimulate the CETP-mediated transfer of cholesteryl esters from HDL to VLDL and LDL .
GPIHBP1 Protein mediates lipid metabolism by transporting lipoprotein lipase LPL, anchoring it in capillaries, and safeguarding against loss of activity. It crucially contributes to chylomicron lipolysis, triglyceride metabolism, and overall lipid homeostasis. The protein binds chylomicrons, APOA5-containing phospholipid particles, and HDL, highlighting its role in lipid interactions and uptake. With predominantly monomeric states and 1:1 stoichiometry in LPL interaction, GPIHBP1 precisely orchestrates lipid processing, emphasizing its significance in vascular lipid transport. GPIHBP1 Protein, Human (HEK293, Fc) is the recombinant human-derived GPIHBP1 protein, expressed by HEK293, with C-hFc labeled tag. The total length of GPIHBP1 Protein, Human (HEK293, Fc) is 130 a.a., with molecular weight of 50-65 kDa.
16:0 PDP PE belongs to a class of head group modified functionalized lipids. 16:0 PDP PE has been used in preparation of rhodamine high-densitylipoprotein nanoparticle (Rh-HDL NP) synthesis.
Inquiry Online
Your information is safe with us. * Required Fields.
